openPR Logo
Press release

Investigation announced for Investors in Nkarta, Inc. (NASDAQ: NKTX) over potential Wrongdoing

02-06-2024 09:13 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Nkarta, Inc. (NASDAQ: NKTX).

Investors who purchased shares of Nkarta, Inc. (NASDAQ: NKTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Nkarta, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Francisco, CA based Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. Nkarta, Inc. reported that its Net Loss increased from $86.07 million in 2021 to $113.83 million in 2022.

Shares of Nkarta, Inc. (NASDAQ: NKTX) declined from $11.62 per share on January 09, 2024, to $7.02 per share on January 19, 2024.

Those who purchased shares of Nkarta, Inc. (NASDAQ: NKTX), have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Nkarta, Inc. (NASDAQ: NKTX) over potential Wrongdoing here

News-ID: 3374698 • Views:

More Releases from Shareholders Foundation

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly NASDAQ: SINA)
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made. If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: FLR) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp. (NYSE: SOC)
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp. Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Nkarta

Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hof …
DelveInsight's, "Lupus Nephritis - Pipeline Insight, 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. DelveInsight reports that the Lupus Nephritis pipeline involves over 35
Natural Killer Cell Therapeutics Market 2025-2032: Rising NK Cell Immunotherapy …
The worldwide "Natural Killer Cell Therapeutics Market" 2025 Research Report presents a professional and complete analysis of the Global Natural Killer Cell Therapeutics Market in the current situation. This report includes development plans and policies along with Natural Killer Cell Therapeutics manufacturing processes and price structures. the reports 2025 research report offers an analytical view of the industry by studying different factors like Natural Killer Cell Therapeutics Market growth, consumption
NK Cells Market Hits New High | Major Giants NantKwest, Fate Therapeutics, Affim …
HTF MI just released the Global NK Cells Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach. Major Giants in NK Cells Market are: NantKwest, Fate Therapeutics, Affimed, Glycostem,
Oncofertility Market 2022 Global Projection By Key Players - Legacy, Nkarta, Akr …
Oncofertility Market 2022 Environmental sciences are being used for creating awareness regarding hygiene and robust health. With adoption of HER/EMR solutions on the rise, the risk of insufficient protection/loopholes can't be ruled out. There is every likelihood of company employees and patients alike getting targeted through sophisticated phishing attacks and social engineering. As such, cybersecurity should be in place, much before AI-organized system is incorporated. The Oncofertility Market would go this
Global Oncofertility Market Growth Analysis, Latest Trends and Forecast till 202 …
Oncofertility is a medical specialty that combines the fields of oncology and reproductive endocrinology to help cancer patients and survivors maximize their reproductive potential. Chemotherapy, radiation, and surgery are among cancer therapies that might make it difficult or impossible to have children later in life. The global Oncofertility market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX
Global natural killer (NK) cell therapeutics market Likely to Experience a Treme …
This Natural Killer (NK) Cell Therapeutics Market analysis report presents an edge to not only compete but also to outshine the competition. Global market research analysis report serves a lot for the business and bestows with the solution for the toughest business problems. This Natural Killer (NK) Cell Therapeutics Market business document gives a detailed synopsis on the study of industry and its impact on the market environment. Market shares